The relationship between depression and generalized anxiety during intensive psychological and pharmacological treatment

Abstract Background In the present study we examined the relationship between depressive symptoms and generalized anxiety symptoms during intensive cognitive-behavioral and pharmacological treatment. Method: Individuals ( n =157) with major depressive disorder (MDD; n =83), generalized anxiety disor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of affective disorders 2015-09, Vol.184, p.261-268
Hauptverfasser: Aderka, Idan M, Beard, Courtney, Lee, Josephine, Weiss, Rachel B, Björgvinsson, Thröstur
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background In the present study we examined the relationship between depressive symptoms and generalized anxiety symptoms during intensive cognitive-behavioral and pharmacological treatment. Method: Individuals ( n =157) with major depressive disorder (MDD; n =83), generalized anxiety disorder (GAD; n =29) and their combination ( n =45) who attended an intensive partial hospital treatment program, completed daily self-report measures of depression and generalized anxiety. Treatment included empirically-based cognitive-behavioral interventions in both individual and group format, as well as pharmacotherapy. Results Multilevel linear modeling indicated that for all diagnostic groups, changes in depressive symptoms led to changes in generalized anxiety symptoms to a greater extent than vice versa during treatment. Moreover, changes in depressive symptoms fully mediated changes in generalized anxiety symptoms, whereas changes in generalized anxiety symptoms only partially mediated the changes in depressive symptoms. Limitations Partial hospital setting. Conclusions Our results suggest that depressive symptoms may play a prominent role in the process of change in both MDD and GAD. This has implications for the classification of GAD as well as for choosing early treatment targets for individuals with comorbid MDD and GAD.
ISSN:0165-0327
1573-2517
DOI:10.1016/j.jad.2015.05.054